Precigen Reports First Quarter 2026 Financial Results and Business Updates
Precigen reported Q1 2026 revenue of $23.252 million, with $21.6 million from the launch of PAPZIMEOS, reflecting strong commercial uptake. Patient hub enrollment for PAPZIMEOS reached approximately 400 patients, with 25% from the community setting, underscoring broad reach and ease of administration. The company will present updated durability of response data for PAPZIMEOS at the upcoming ASCO Annual Meeting, further validating its clinical performance.
Key figures
- Eps Beat
- 0
- Revenue
- 23252000
- Guidance
- Cash, cash equivalents, and investments totaled $56.7 million as of March 31, 2026, expected to fund operations to cash flow break-even by the end of 2026.
- Revenue Yoy
- 1630%
- Net loss
- 7929000
- Accounts receivable
- 26403000
- Net product revenue
- 21600000
- Patient hub enrollment
- 400
- Medicare medicaid coverage
- 297000000
- Private health plan coverage
- 215000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.